Can GAP double the number of patients in Alzheimer’s trials?

Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than 30 percent of total trial time is spent simply recruiting patients.

Those issues are present in all therapeutic areas, including Alzheimer’s disease. To mitigate these problems, cut the time of trials, and get needed medicines to patients faster, the Global Alzheimer’s Platform (GAP) Foundation is implementing a new model. The model promises to both accelerate clinical trials and increase patient participation in Alzheimer’s clinical research.

According to GAP, Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers more than $153 billion per year in Medicare and Medicaid expenses. By the year 2050, it’s estimated that 14 million Americans will be afflicted with the disease. With the aging population we currently have in this country, finding an effective treatment for the disease has never been more important.

Read the full article online here.